Tenofovir disoproxil fumarate, Lamivudine, Atazanavir, Ritonavir

Tenofovir disoproxil fumarate, lamivudine, atazanavir, and ritonavir are antiretroviral medications used to treat HIV-1 infection. This combination medication, known as Atripla, works by inhibiting the viral replication process and helping the immune system recover.
Atripla contains two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate and lamivudine, which block the action of an enzyme called reverse transcriptase. This enzyme is crucial for the virus to replicate and cause damage to the immune system.
In addition to the NRTIs, Atripla also includes two protease inhibitors, atazanavir and ritonavir. Protease inhibitors target another enzyme called protease, which is necessary for the production of viral proteins. Ritonavir, in particular, is a booster that enhances the effectiveness of atazanavir by increasing its concentration in the bloodstream.
Atripla is typically prescribed as a once-daily treatment for adults diagnosed with HIV-1 infection. The medication aims to reduce the viral load in the body, slow down the progression of the disease, and improve the quality of life for patients. Take Atripla exactly as prescribed and to undergo regular blood tests to monitor its effectiveness and potential side effects.